Published in Clin Pharmacol Ther on July 01, 2002
Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med (2004) 5.59
Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol (2009) 3.43
Growth factor delivery-based tissue engineering: general approaches and a review of recent developments. J R Soc Interface (2010) 2.69
Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction. Nat Biotechnol (2013) 2.11
Polymorphisms in VEGFA gene affect the antihypertensive responses to enalapril. Eur J Clin Pharmacol (2015) 2.03
A compartment model of VEGF distribution in blood, healthy and diseased tissues. BMC Syst Biol (2008) 1.50
Enhanced Mitogenic Activity of Recombinant Human Vascular Endothelial Growth Factor VEGF121 Expressed in E. coli Origami B (DE3) with Molecular Chaperones. PLoS One (2016) 1.38
The vasa vasorum in diseased and nondiseased arteries. Am J Physiol Heart Circ Physiol (2009) 1.28
Controlled delivery of VEGF via modulation of alginate microparticle ionic crosslinking. J Control Release (2008) 1.23
Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeys. AAPS J (2010) 1.10
A compartment model of VEGF distribution in humans in the presence of soluble VEGF receptor-1 acting as a ligand trap. PLoS One (2009) 1.09
Targeted delivery of nanoparticles to ischemic muscle for imaging and therapeutic angiogenesis. Nano Lett (2010) 1.08
Promoting angiogenesis via manipulation of VEGF responsiveness with notch signaling. Biomaterials (2009) 1.00
The presence of VEGF receptors on the luminal surface of endothelial cells affects VEGF distribution and VEGF signaling. PLoS Comput Biol (2009) 0.96
Sequential delivery of vascular endothelial growth factor and sphingosine 1-phosphate for angiogenesis. Biomaterials (2010) 0.94
Formation of VEGF isoform-specific spatial distributions governing angiogenesis: computational analysis. BMC Syst Biol (2011) 0.94
Arterio-venous gradients of IL-6, plasma and serum VEGF and D-dimers in human cancer. Br J Cancer (2002) 0.93
Delivery of VEGF using collagen-coated polycaprolactone scaffolds stimulates angiogenesis. J Biomed Mater Res A (2011) 0.92
Matrix-based gene delivery for tissue repair. Curr Opin Biotechnol (2013) 0.92
Driving vascular endothelial cell fate of human multipotent Isl1+ heart progenitors with VEGF modified mRNA. Cell Res (2013) 0.90
A mechanism-based model for the population pharmacokinetics of free and bound aflibercept in healthy subjects. Br J Clin Pharmacol (2011) 0.89
Cell-free 3D scaffold with two-stage delivery of miRNA-26a to regenerate critical-sized bone defects. Nat Commun (2016) 0.89
Cytokine-release kinetics of platelet-rich plasma according to various activation protocols. Bone Joint Res (2016) 0.88
Mucosally transplanted mesenchymal stem cells stimulate intestinal healing by promoting angiogenesis. J Clin Invest (2015) 0.87
Noninvasive assessment of tumor VEGF receptors in response to treatment with pazopanib: a molecular imaging study. Transl Oncol (2010) 0.87
Vascular endothelial growth factor-delivery systems for cardiac repair: an overview. Theranostics (2012) 0.87
Exogenous recombinant dimeric neuropilin-1 is sufficient to drive angiogenesis. J Biol Chem (2010) 0.86
Maternally sequestered therapeutic polypeptides - a new approach for the management of preeclampsia. Front Pharmacol (2014) 0.83
Angiogenic therapy for cardiac repair based on protein delivery systems. Heart Fail Rev (2012) 0.83
New approaches for managing preeclampsia: clues from clinical and basic research. Clin Ther (2014) 0.83
A Tutorial on Target-Mediated Drug Disposition (TMDD) Models. CPT Pharmacometrics Syst Pharmacol (2015) 0.83
Growth factor purification and delivery systems (PADS) for therapeutic angiogenesis. Vasc Cell (2015) 0.82
Sustained delivery of VEGF maintains innervation and promotes reperfusion in ischemic skeletal muscles via NGF/GDNF signaling. Mol Ther (2014) 0.82
Avidity-controlled delivery of angiogenic peptides from injectable molecular-recognition hydrogels. Tissue Eng Part A (2014) 0.81
Effect of vascular endothelial growth factor gene therapy on post-traumatic peripheral nerve regeneration and denervation-related muscle atrophy. Gene Ther (2013) 0.81
Serum-dependence of affinity-mediated VEGF release from biomimetic microspheres. Biomacromolecules (2014) 0.80
Multivalent Conjugates of Sonic Hedgehog Accelerate Diabetic Wound Healing. Tissue Eng Part A (2015) 0.79
Integration of drug, protein, and gene delivery systems with regenerative medicine. Drug Deliv Transl Res (2015) 0.79
One-pot Synthesis of Elastin-like Polypeptide Hydrogels with Grafted VEGF-Mimetic Peptides. Biomater Sci (2014) 0.79
Nano-nutrition of chicken embryos. The effect of in ovo administration of diamond nanoparticles and L-glutamine on molecular responses in chicken embryo pectoral muscles. Int J Mol Sci (2013) 0.78
Use of natural neural scaffolds consisting of engineered vascular endothelial growth factor immobilized on ordered collagen fibers filled in a collagen tube for peripheral nerve regeneration in rats. Int J Mol Sci (2014) 0.78
Neovascularization in tissue engineering. Cells (2012) 0.77
Nanodiamond-based injectable hydrogel for sustained growth factor release: preparation, characterization and in vitro analysis. Acta Biomater (2017) 0.77
The Small Molecule R-(-)-β-O-Methylsynephrine Binds to Nucleoporin 153 kDa and Inhibits Angiogenesis. Int J Biol Sci (2015) 0.76
A mathematical model for the onset of avascular tumor growth in response to the loss of p53 function. Cancer Inform (2007) 0.76
Target-mediated disposition model describing the dynamics of IL12 and IFNγ after administration of a mifepristone-inducible adenoviral vector for IL-12 expression in mice. AAPS J (2012) 0.75
Pediatric Dosing and Body Size in Biotherapeutics. Pharmaceutics (2010) 0.75
The Good the Bad and the Ugly of Glycosaminoglycans in Tissue Engineering Applications. Pharmaceuticals (Basel) (2017) 0.75
VEGF and IGF Delivered from Alginate Hydrogels Promote Stable Perfusion Recovery in Ischemic Hind Limbs of Aged Mice and Young Rabbits. J Vasc Res (2017) 0.75
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med (2004) 11.86
A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol (2009) 8.13
Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet (2003) 6.85
Prevalence of conventional risk factors in patients with coronary heart disease. JAMA (2003) 6.84
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol (2011) 6.35
Circadian dependence of infarct size and left ventricular function after ST elevation myocardial infarction. Circ Res (2011) 5.87
Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med (2007) 5.37
Efficacy of a device to narrow the coronary sinus in refractory angina. N Engl J Med (2015) 5.36
Aging, progenitor cell exhaustion, and atherosclerosis. Circulation (2003) 5.19
Radial artery bypass grafts have an increased occurrence of angiographically severe stenosis and occlusion compared with left internal mammary arteries and saphenous vein grafts. Circulation (2004) 4.13
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet (2013) 3.74
Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res (2011) 3.72
Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA (2008) 3.64
Prediction of coronary heart disease risk using a genetic risk score: the Atherosclerosis Risk in Communities Study. Am J Epidemiol (2007) 3.48
The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation (2003) 3.45
Bare metal stent restenosis is not a benign clinical entity. Am Heart J (2006) 3.39
Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet (2002) 3.31
One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation (2004) 3.23
Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet (2013) 3.17
Multicenter validation of the diagnostic accuracy of a blood-based gene expression test for assessing obstructive coronary artery disease in nondiabetic patients. Ann Intern Med (2010) 3.17
Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol (2010) 3.06
"False-positive" cardiac catheterization laboratory activation among patients with suspected ST-segment elevation myocardial infarction. JAMA (2007) 2.89
Patients with coronary artery disease not amenable to traditional revascularization: prevalence and 3-year mortality. Catheter Cardiovasc Interv (2010) 2.88
Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial. Circulation (2007) 2.88
Stent thrombosis. J Am Coll Cardiol (2010) 2.86
Myocardial injury and long-term mortality following moderate to severe carbon monoxide poisoning. JAMA (2006) 2.83
ST-elevation myocardial infarction diagnosed after hospital admission. Circulation (2014) 2.83
Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation (2008) 2.82
A quantitative trait locus (LSq-1) on mouse chromosome 7 is linked to the absence of tissue loss after surgical hindlimb ischemia. Circulation (2008) 2.77
Angiographic surrogate end points in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized, controlled trials. J Am Coll Cardiol (2008) 2.54
A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease. Arterioscler Thromb Vasc Biol (2007) 2.47
Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation (2002) 2.39
Association of gene variants with incident myocardial infarction in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol (2007) 2.36
A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest (2003) 2.32
Cardiovascular manifestations of moderate to severe carbon monoxide poisoning. J Am Coll Cardiol (2005) 2.19
Percutaneous coronary intervention in patients with severe aortic stenosis: implications for transcatheter aortic valve replacement. Circulation (2012) 2.17
Impact of post-intervention minimal stent area on 9-month follow-up patency of paclitaxel-eluting stents: an integrated intravascular ultrasound analysis from the TAXUS IV, V, and VI and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent Trials. JACC Cardiovasc Interv (2009) 2.12
Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. JAMA (2006) 2.03
Procedural variation in the performance of primary percutaneous coronary intervention for ST-elevation myocardial infarction: a SCAI-based survey study of US interventional cardiologists. Catheter Cardiovasc Interv (2013) 2.02
Renal failure after percutaneous coronary intervention is associated with high mortality. Catheter Cardiovasc Interv (2005) 2.00
Usefulness of an elevated neutrophil to lymphocyte ratio in predicting long-term mortality after percutaneous coronary intervention. Am J Cardiol (2006) 2.00
Benefit of transferring ST-segment-elevation myocardial infarction patients for percutaneous coronary intervention compared with administration of onsite fibrinolytic declines as delays increase. Circulation (2011) 1.95
Identification of four gene variants associated with myocardial infarction. Am J Hum Genet (2005) 1.89
Development of a network to test strategies in cardiovascular cell delivery: the NHLBI-sponsored Cardiovascular Cell Therapy Research Network (CCTRN). J Cardiovasc Transl Res (2010) 1.84
The VEGF receptor Flt-1 spatially modulates Flk-1 signaling and blood vessel branching. J Cell Biol (2008) 1.82
Percutaneous transvenous mitral annuloplasty: initial human experience with a novel coronary sinus implant device. Circ Cardiovasc Interv (2009) 1.77
Polymer-based paclitaxel-eluting stents reduce in-stent neointimal tissue proliferation: a serial volumetric intravascular ultrasound analysis from the TAXUS-IV trial. J Am Coll Cardiol (2005) 1.74
Recommendations for successful training on methods of delivery of biologics for cardiac regeneration: a report of the International Society for Cardiovascular Translational Research. JACC Cardiovasc Interv (2010) 1.74
Five common gene variants identify elevated genetic risk for coronary heart disease. Genet Med (2007) 1.72
Voluntary running induces fiber type-specific angiogenesis in mouse skeletal muscle. Am J Physiol Cell Physiol (2004) 1.71
Early risk of mortality after coronary artery revascularization in patients with left ventricular dysfunction and potential role of the wearable cardioverter defibrillator. Circ Arrhythm Electrophysiol (2012) 1.66
Atherosclerotic Vascular Disease Conference: Writing Group III: pathophysiology. Circulation (2004) 1.65
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Catheter Cardiovasc Interv (2012) 1.65
Hypersensitivity reactions associated with endovascular devices. Contact Dermatitis (2008) 1.63
Relationship between intravascular ultrasound guidance and clinical outcomes after drug-eluting stents: the assessment of dual antiplatelet therapy with drug-eluting stents (ADAPT-DES) study. Circulation (2013) 1.62
Increased prevalence of coronary artery aneurysms among cocaine users. Circulation (2005) 1.60
Emergency coronary artery bypass surgery in the contemporary percutaneous coronary intervention era. Circulation (2002) 1.60
Gene variants of VAMP8 and HNRPUL1 are associated with early-onset myocardial infarction. Arterioscler Thromb Vasc Biol (2006) 1.60
Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial. J Am Coll Cardiol (2005) 1.59
A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use. J Cell Mol Med (2009) 1.59
Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation (2002) 1.58
Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother Pharmacol (2012) 1.57
Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation (2003) 1.55
Predictors of revascularization method and long-term outcome of percutaneous coronary intervention or repeat coronary bypass surgery in patients with multivessel coronary disease and previous coronary bypass surgery. Eur Heart J (2005) 1.54
LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction. Tex Heart Inst J (2010) 1.52
Causes of delay and associated mortality in patients transferred with ST-segment-elevation myocardial infarction. Circulation (2011) 1.49
Percutaneous intervention in peripheral artery disease improves calf muscle phosphocreatine recovery kinetics: a pilot study. Vasc Med (2012) 1.48
Cause of death within 30 days of percutaneous coronary intervention in an era of mandatory outcome reporting. J Am Coll Cardiol (2013) 1.48
Safety and efficacy of a pharmaco-invasive reperfusion strategy in rural ST-elevation myocardial infarction patients with expected delays due to long-distance transfers. Eur Heart J (2011) 1.46
Elevated T-wave alternans predicts nonsustained ventricular tachycardia in association with percutaneous coronary intervention in ST-segment elevation myocardial infarction (STEMI) patients. J Cardiovasc Electrophysiol (2013) 1.46
Quality improvement in the door-to-balloon times for ST-elevation myocardial infarction patients presenting without chest pain. Catheter Cardiovasc Interv (2011) 1.46
The prognostic role of mitral regurgitation after primary percutaneous coronary intervention for acute ST-elevation myocardial infarction. Catheter Cardiovasc Interv (2012) 1.45
Enoxaparin in primary and facilitated percutaneous coronary intervention A formal prospective nonrandomized substudy of the FINESSE trial (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events). JACC Cardiovasc Interv (2010) 1.45
An integrated TAXUS IV, V, and VI intravascular ultrasound analysis of the predictors of edge restenosis after bare metal or paclitaxel-eluting stents. Am J Cardiol (2008) 1.44
Arteriotomy closure device safety after percutaneous coronary intervention in the direct thrombin inhibitor era: a comparative study. Catheter Cardiovasc Interv (2012) 1.44
New generation drug-eluting stents for ST-elevation myocardial infarction: a new paradigm for safety. Catheter Cardiovasc Interv (2014) 1.44
Rescue percutaneous coronary intervention after failed fibrinolytic therapy: have expectations been met? Am Heart J (2006) 1.44
Influence of sex on long-term outcomes after percutaneous coronary intervention with the paclitaxel-eluting coronary stent: results of the "TAXUS Woman" analysis. JACC Cardiovasc Interv (2010) 1.43
Recombinant tissue plasminogen activator (alteplase) for restoration of function to occluded central venous catheters in pediatric patients. J Pediatr Hematol Oncol (2003) 1.43
Preclinical models of human peripheral arterial occlusive disease: implications for investigation of therapeutic agents. J Appl Physiol (1985) (2004) 1.43